Johnson & Johnson

Johnson & Johnson is an American multinational healthcare company that researches, develops, manufactures, and sells pharmaceuticals and medical technologies across virtually every country in the world, generating $94.2 billion in revenue in fiscal 2025. With approximately 138,200 employees, a $574 billion market capitalization, and 64 consecutive years of dividend increases, J&J is among the largest and most durable enterprises in the healthcare sector — and one of only two U.S. companies to carry a AAA credit rating from Standard & Poor's.

This is a story about whether the company's strongest-ever product portfolio and pipeline can deliver on a specific promise: double-digit revenue growth by the end of the decade, at a scale of over $100 billion. The bull case is straightforward — J&J has already demonstrated it can grow at double digits when you strip out STELARA's biosimilar erosion, a drag that is largely in the rearview mirror after declining 59.7% year-over-year in the first quarter of 2026. The question is whether the new launches — ICOTYDE, CAPLYTA, CARVYKTI, INLEXZO, TREMFYA's expanding indications, the next-generation PFA electrophysiology catheters, and the OTTAVA robotic surgery platform — collectively generate enough lift to offset the headwinds that remain: DARZALEX's 2029 patent cliff, IRA drug pricing, tariffs, and a structural margin difference between pharmaceuticals and devices. The file turns on whether the pipeline is genuinely as deep as management claims, or whether the transparency of J&J's numbers — distorted in recent years by multi-billion-dollar talc litigation charges and reversals — masks a more prosaic story of a mature conglomerate.